TFA Therapeutics (RAJAF) Retained Earnings (2020 - 2025)

TFA Therapeutics has reported Retained Earnings for 6 years, with the latest figure at -$854046.0 in Q4 2025.

• On a quarterly basis, Retained Earnings fell 22.14% year-over-year to -$854046.0 in Q4 2025; TTM through Dec 2025 was -$854046.0, a 22.14% decrease from a year earlier, with the FY2025 full-year figure at -$854046.0, down 22.14% from the prior year.
• Retained Earnings was -$854046.0 for Q4 2025 at TFA Therapeutics, down from -$699224.0 in the prior quarter.
• The five-year high for Retained Earnings was $221288.0 in Q3 2023, with the low at -$1.2 million in Q4 2022.
• Average Retained Earnings over 5 years is -$589000.8, with a median of -$601853.0 recorded in 2021.
• The sharpest annual moves came in 2021 and 2023: Retained Earnings slumped 3643.56% in 2021, then surged 61.38% in 2023.
• Over 5 years, Retained Earnings stood at -$504482.0 in 2021, then tumbled by 142.74% to -$1.2 million in 2022, then soared by 61.38% to -$472966.0 in 2023, then slumped by 47.84% to -$699224.0 in 2024, then declined by 22.14% to -$854046.0 in 2025.
• The last three Retained Earnings figures came in at -$854046.0 (Q4 2025), -$699224.0 (Q4 2024), and -$472966.0 (Q4 2023), per Business Quant data.